<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358666</url>
  </required_header>
  <id_info>
    <org_study_id>19-086</org_study_id>
    <nct_id>NCT04358666</nct_id>
  </id_info>
  <brief_title>Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis</brief_title>
  <acronym>OPTMETACER</acronym>
  <official_title>Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main Goal : evaluation of quality of life for patient having a brain metastasis and allowed
      to have either surgery and radiosurgery of the surgical site or only hypofractionned
      radiosurgery on the lesion.

      second objectives : evaluation of the local control of the disease evaluation of the overall
      survival interval without progression evaluation of the medico economic performance of each
      treatment protocol neuro cognitive evaluation at the end of the protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A patient with a brain metastasis may have the choice between surgery and focal radiosurgery
      of the surgical site and only hypofractionned radiosurgery on the lesion.

      No previous study has focused on quality of life regarding these two treatments options.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomization between surgery and focal radiosurgery of the surgical site and hypofractionned radiosurgery of the tumor</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life EORTC QLQ C30</measure>
    <time_frame>change between baseline and 6 month</time_frame>
    <description>score European Organisation for Research and Treatment of Cancer Quality Life Quotation C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control of the desease</measure>
    <time_frame>baseline up to 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival without progression</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medico economic evaluation</measure>
    <time_frame>24 month</time_frame>
    <description>cost-utility analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuro cognitive evaluation</measure>
    <time_frame>12 and 24 month</time_frame>
    <description>BOSTON NAMING TEST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Quality of Life</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>surgery and focal radiosurgery of the surgical site</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hypofractionned radiosurgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery and focal radiosurgery of the surgical bed</intervention_name>
    <description>hypofractionned radiosurgery of the lesion</description>
    <arm_group_label>hypofractionned radiosurgery</arm_group_label>
    <arm_group_label>surgery and focal radiosurgery of the surgical site</arm_group_label>
    <other_name>hypofractionned radiosurgery of the lesion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eligible for both treatments options OMS status &lt;3 primary cancer with no evolution
             brain metastasis &lt; 3cm ou giving symtoms patient with informed consent patient
             affilated to french social security

        Exclusion Criteria:

          -  OMS &gt; 3 More than 3 brain metastasis brain metastasis already treated with
             hypofractionned radiosurgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyne Emery, MD PhD</last_name>
      <phone>+33 2064605</phone>
      <email>emery-e@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>jean jacques Dutheil, PhD</last_name>
      <phone>+33 231065351</phone>
      <email>dutheil-jj@chu-caen.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastasis, best treatment, quality of life, surgery+radiosurgery, hypofractionned radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

